Abid Hussain is an emerging scientist holding a Ph.D. in Drug Delivery, specialized in nano-medicines for cancer therapy.
Having served as a formulation manager in a renowned pharmaceutical industry, he has contributed to the development of three patents, registered with WIPO and protected under PCT. Additionally, played a pivotal role in the submission process of two pharmaceutical products to EMA during 2020-2021.
Furthermore, his expertise extends to nucleic acid therapeutics for treating tumors, hyperlipidemia, and hyperuricemia. He has authored numerous publications in prestigious journals, serving as the first author, co-author, and corresponding author. These publications have garnered over 800 citations, with an h-index of 15 and an i10 index of 20.
Currently, Abid is working as an Academic Research Associate leading projects comprising active targeting of cardiovascular disease and tumor via ligand-conjugated Lipid Nanoparticles encapsulating mRNA/siRNA and ligand-conjugated polymeric NPs.
Abid Hussain is an emerging scientist holding a Ph.D. in Drug Delivery, specialized in nano-medicines for cancer therapy.
Having served as a formulation manager in a renowned pharmaceutical industry, he has contributed to the development of three patents, registered with WIPO and protected under PCT. Additionally, played a pivotal role in the submission process of two pharmaceutical products to EMA during 2020-2021.
Furthermore, his expertise extends to nucleic acid therapeutics for treating tumors, hyperlipidemia, and hyperuricemia. He has authored numerous publications in prestigious journals, serving as the first author, co-author, and corresponding author. These publications have garnered over 800 citations, with an h-index of... Read more
About me
Abid Hussain is an emerging scientist holding a Ph.D. in Drug Delivery, specialized in nano-medicines for cancer therapy.
Having served as a formulation manager in a renowned pharmaceutical industry, he has contributed to the development of three patents, registered with WIPO and protected under PCT. Additionally, played a pivotal role in the submission process of two pharmaceutical products to EMA during 2020-2021.
Furthermore, his expertise extends to nucleic acid therapeutics for treating tumors, hyperlipidemia, and hyperuricemia. He has authored numerous publications in prestigious journals, serving as the first author, co-author, and corresponding author. These publications have garnered over 800 citations, with an h-index of 15 and an i10 index of 20.
Currently, Abid is working as an Academic Research Associate leading projects comprising active targeting of cardiovascular disease and tumor via ligand-conjugated Lipid Nanoparticles encapsulating mRNA/siRNA and ligand-conjugated polymeric NPs.
About me
Doctor of Philosophy Shanghai Jiao Tong University
Doctor of Pharmacy Gomal University
Master of Philosophy University of Malakand
Abid Hussain is an emerging scientist holding a Ph.D. in Drug Delivery, specialized in nano-medicines for cancer therapy.
Having served as a formulation manager in a renowned pharmaceutical industry, he has contributed to the development of three patents, registered with WIPO and protected under PCT. Additionally, played a pivotal role in the submission process of two pharmaceutical products to EMA during 2020-2021.
Furthermore, his expertise extends to nucleic acid therapeutics for treating tumors, hyperlipidemia, and hyperuricemia. He has authored numerous publications in prestigious journals, serving as the first author, co-author, and corresponding author. These publications have garnered over 800 citations, with an h-index of... Read more
Research
Research outputs for the last seven years are shown below. Some long-standing staff members may have older outputs included. To see earlier years visit ORCID or Scopus
Open access indicates that an output is open access.
Year | Output |
---|---|
2022 |
1
|
2022 |
5
|
2022 |
6
|
Year | Output |
---|---|
2024 |
Open access
1
|
2023 |
6
4
|
2023 |
13
13
16
|
2022 |
Open access
53
53
3
|
2022 |
66
58
2
|
2022 |
53
57
7
|
2022 |
Open access
47
43
4
|
2022 |
Open access
13
11
|
2022 |
13
12
1
|
2022 |
Open access
18
15
1
|
2022 |
12
11
11
|
2021 |
Open access
126
|
2021 |
68
69
|
2021 |
20
19
2
|
2021 |
Open access
14
12
2
|
2019 |
23
22
1
|
2019 |
16
15
1
|
2017 |
12
11
|
2017 |
29
27
1
|
2017 |
31
24
3
|
2016 |
68
62
3
|
Research
Abid Hussain is an emerging scientist holding a Ph.D. in Drug Delivery, specialized in nano-medicines for cancer therapy.
Having served as a formulation manager in a renowned pharmaceutical industry, he has contributed to the development of three patents, registered with WIPO and protected under PCT. Additionally, played a pivotal role in the submission process of two pharmaceutical products to EMA during 2020-2021.
Furthermore, his expertise extends to nucleic acid therapeutics for treating tumors, hyperlipidemia, and hyperuricemia. He has authored numerous publications in prestigious journals, serving as the first author, co-author, and corresponding author. These publications have garnered over 800 citations, with an h-index of 15 and an i10 index of 20.
Currently, Abid is working as an Academic Research Associate leading projects comprising active targeting of cardiovascular disease and tumor via ligand-conjugated Lipid Nanoparticles encapsulating mRNA/siRNA and ligand-conjugated polymeric NPs.
External engagement & recognition
Organisation | Country |
---|---|
Abasyn University | PAKISTAN |
Affiliated Hospital of Nantong University | CHINA |
Aix-Marseille University | FRANCE |
Beijing Institute of Technology | CHINA |
Capital University of Science and Technology | PAKISTAN |
China Pharmaceutical University | CHINA |
Chinese Academy of Sciences | CHINA |
Chinese PLA General Hospital | CHINA |
Guangxi Medical University | CHINA |
Guangzhou Medical University | CHINA |
Hebei University | CHINA |
Henan Normal University | CHINA |
Jiangnan University | CHINA |
Jiangsu University | CHINA |
Nankai University | CHINA |
Nantong University | CHINA |
National Center for Nanoscience and Technology of China | CHINA |
Nestlives Private Limited | INDIA |
Peking University | CHINA |
Quaid-i-Azam University | PAKISTAN |
Shandong University | CHINA |
Shanghai Jiao Tong University | CHINA |
Shanghai University | CHINA |
Shanghai Veterinary Research Institute | CHINA |
Shantou University | CHINA |
Shantou University Medical College | CHINA |
Shaqra University | SAUDI ARABIA |
Shenzhen University | CHINA |
Soochow University | TAIWAN |
Tianjin Medical University | CHINA |
Tianjin University | CHINA |
University of California | UNITED STATES |
University of Macau | MACAU (SAR OF CHINA) |
University of Malakand | PAKISTAN |
University of Texas Southwestern Medical Center | UNITED STATES |
Women's and Children's Hospital | AUSTRALIA |
Yangzhou University | CHINA |
Yantai University | CHINA |
Zhejiang University | CHINA |
Zhengzhou University | CHINA |